BR112022001365A2 - Formas cristalinas de um inibidor de cd73 - Google Patents
Formas cristalinas de um inibidor de cd73Info
- Publication number
- BR112022001365A2 BR112022001365A2 BR112022001365A BR112022001365A BR112022001365A2 BR 112022001365 A2 BR112022001365 A2 BR 112022001365A2 BR 112022001365 A BR112022001365 A BR 112022001365A BR 112022001365 A BR112022001365 A BR 112022001365A BR 112022001365 A2 BR112022001365 A2 BR 112022001365A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline forms
- inhibitor
- isopropylcyclopropyl
- pyridazin
- dione
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
formas cristalinas de um inibidor de cd73. a presente invenção refere-se a formas cristalinas de 5-[5-[2-isopropilciclopropil]-6-metil-piridazin-3-il]-1h-pirimidina-2,4-diona, e composições farmacêuticas que as compreendem, que inibem a atividade de cd73 e são úteis para o tratamento do câncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382733 | 2019-08-29 | ||
| PCT/US2020/047645 WO2021041319A1 (en) | 2019-08-29 | 2020-08-24 | Crystalline forms of a cd73 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022001365A2 true BR112022001365A2 (pt) | 2022-06-07 |
Family
ID=67902444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022001365A BR112022001365A2 (pt) | 2019-08-29 | 2020-08-24 | Formas cristalinas de um inibidor de cd73 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220289716A1 (pt) |
| EP (1) | EP4021902B1 (pt) |
| JP (1) | JP7292501B2 (pt) |
| KR (1) | KR20220038453A (pt) |
| CN (1) | CN114502548A (pt) |
| AU (1) | AU2020340299B2 (pt) |
| BR (1) | BR112022001365A2 (pt) |
| CA (1) | CA3147998A1 (pt) |
| IL (1) | IL289929A (pt) |
| MX (1) | MX2022002398A (pt) |
| WO (1) | WO2021041319A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230321100A1 (en) * | 2020-09-08 | 2023-10-12 | Betta Pharmaceuticals Co., Ltd | Cd73 inhibitor and application thereof in medicine |
| EP4242204A1 (en) * | 2020-11-05 | 2023-09-13 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Cd73 inhibitor and use thereof |
| CN116134029A (zh) * | 2020-12-10 | 2023-05-16 | 上海翰森生物医药科技有限公司 | 氧代氮环类衍生物调节剂、其制备方法和应用 |
| WO2023169327A1 (zh) * | 2022-03-07 | 2023-09-14 | 贝达药业股份有限公司 | 一种哒嗪类衍生物的晶型、制备方法及其应用 |
| WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101461801B (zh) * | 2008-12-26 | 2013-05-15 | 辰欣药业股份有限公司 | 一种奥沙利铂药物组合物及其制备方法 |
| ES2916825T3 (es) * | 2014-01-20 | 2022-07-06 | UCB Biopharma SRL | Procedimiento para la reconstitución de una forma sólida de una composición farmacéutica |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| CN108697719B (zh) * | 2016-01-08 | 2024-03-19 | 艾库斯生物科学有限公司 | 胞外5′-核苷酸酶的调节剂及其用途 |
| TWI702954B (zh) * | 2018-03-01 | 2020-09-01 | 美商美國禮來大藥廠 | Cd73抑制劑 |
-
2020
- 2020-08-24 BR BR112022001365A patent/BR112022001365A2/pt unknown
- 2020-08-24 MX MX2022002398A patent/MX2022002398A/es unknown
- 2020-08-24 JP JP2022513100A patent/JP7292501B2/ja active Active
- 2020-08-24 AU AU2020340299A patent/AU2020340299B2/en active Active
- 2020-08-24 CA CA3147998A patent/CA3147998A1/en active Pending
- 2020-08-24 US US17/638,341 patent/US20220289716A1/en active Pending
- 2020-08-24 CN CN202080064350.8A patent/CN114502548A/zh active Pending
- 2020-08-24 KR KR1020227006142A patent/KR20220038453A/ko not_active Application Discontinuation
- 2020-08-24 EP EP20764911.2A patent/EP4021902B1/en active Active
- 2020-08-24 WO PCT/US2020/047645 patent/WO2021041319A1/en active Application Filing
-
2022
- 2022-01-17 IL IL289929A patent/IL289929A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022546037A (ja) | 2022-11-02 |
| AU2020340299A1 (en) | 2022-02-17 |
| AU2020340299B2 (en) | 2023-10-26 |
| EP4021902B1 (en) | 2024-03-20 |
| CN114502548A (zh) | 2022-05-13 |
| WO2021041319A1 (en) | 2021-03-04 |
| KR20220038453A (ko) | 2022-03-28 |
| MX2022002398A (es) | 2022-03-17 |
| JP7292501B2 (ja) | 2023-06-16 |
| EP4021902A1 (en) | 2022-07-06 |
| CA3147998A1 (en) | 2021-03-04 |
| US20220289716A1 (en) | 2022-09-15 |
| IL289929A (en) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022001365A2 (pt) | Formas cristalinas de um inibidor de cd73 | |
| BR112019004100A2 (pt) | compostos de biarila úteis como imunomoduladores | |
| BR112018003026A2 (pt) | composições compreendendo um inibidor de pi3k e um inibidor de hdac | |
| BR112018007381A2 (pt) | compostos úteis como imunomoduladores | |
| NZ742742A (en) | Compositions and methods for inhibiting arginase activity | |
| BR112017020999A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
| MX2018006287A (es) | Inhibidores de acc de triazol y usos de los mismos. | |
| BR112015032595A2 (pt) | inibidores de ido | |
| BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| PH12017502051A1 (en) | TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | |
| BR112012024822B8 (pt) | Composto, uso de um composto e composição farmacêutica | |
| CL2017002856A1 (es) | Compuestos de tioéter como inhibidores de la nitrificación | |
| BR112022008365A2 (pt) | Inibidores de cd73 | |
| PH12016502130A1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| DOP2016000312A (es) | Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2 | |
| CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| BR112014018670A8 (pt) | Compostos de fórmula, composição farmacêutica, uso de um composto, método para o tratamento e invenção | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| BR112023018619A2 (pt) | Inibidores de heteroaril de calicreína plasmática | |
| BR112019001158A2 (pt) | formas de succinato e composições de inibidores da tirosina quinase de bruton | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| BR112021017710A2 (pt) | Composto, composição farmacêutica, método de tratamento |